What is HC Wainwright's Estimate for Evolus Q2 Earnings?

Key Points

• HC Wainwright initiated its Q2 2026 outlook for Evolus with an estimate of -$0.07 EPS, while keeping a Buy rating and a $13 price target on the stock.
• Evolus recently reported Q1 earnings of -$0.16 EPS, missing expectations by $0.02, though revenue of $73.14 million slightly topped analyst estimates.
• Broader analyst sentiment remains cautiously positive, with the stock carrying a Moderate Buy consensus and an average $16 price target, despite recent insider selling and mixed ratings changes.

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Stock analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for Evolus in a research report issued to clients and investors on Tuesday, May 5th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.07) per share for the quarter. HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evolus' Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.04 EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.53 EPS, FY2029 earnings at $0.91 EPS and FY2030 earnings at $1.26 EPS.

Other research analysts have also recently issued research reports about the company. Mizuho set a $15.00 price objective on Evolus in a research report on Wednesday, February 4th. Stifel Nicolaus cut their price objective on Evolus from $20.00 to $17.00 and set a "buy" rating on the stock in a research report on Tuesday, January 13th. Wall Street Zen cut Evolus from a "buy" rating to a "hold" rating in a research report on Sunday, March 15th. BTIG Research reissued a "buy" rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, March 4th. Finally, Weiss Ratings cut Evolus from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

Evolus Stock Performance

EOLS stock opened at $6.36 on Monday. The stock's fifty day simple moving average is $4.80 and its two-hundred day simple moving average is $5.63. Evolus has a 1-year low of $3.86 and a 1-year high of $10.62. The stock has a market cap of $418.87 million, a P/E ratio of -9.49 and a beta of 1.28.

Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same period in the prior year, the business earned ($0.30) EPS.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 13,669 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the sale, the insider owned 604,700 shares of the company's stock, valued at approximately $2,872,325. This represents a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the sale, the insider directly owned 430,542 shares in the company, valued at $2,105,350.38. This trade represents a 6.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 163,504 shares of company stock worth $797,184 in the last three months. 5.00% of the stock is currently owned by insiders.

Institutional Trading of Evolus

Institutional investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue purchased a new stake in Evolus during the 3rd quarter worth about $26,000. Larson Financial Group LLC increased its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock worth $33,000 after purchasing an additional 2,837 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Evolus in the fourth quarter worth $34,000. Wexford Capital LP bought a new position in shares of Evolus in the third quarter worth $37,000. Finally, Tower Research Capital LLC TRC boosted its stake in Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company's stock valued at $68,000 after buying an additional 5,691 shares during the period. Hedge funds and other institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.